Literature DB >> 29712435

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.

Amit A Joharapurkar1, Vrajesh B Pandya1, Vishal J Patel1, Ranjit C Desai1, Mukul R Jain1.   

Abstract

Chronic kidney disease, cancer, chronic inflammatory disorders, nutritional, and genetic deficiency can cause anemia. Hypoxia causes induction of hypoxia-inducible factor (HIF), which stimulates erythropoietin (EPO) synthesis. Prolyl hydroxylase domain (PHD) enzyme inhibition can stabilize hypoxia-inducible factor (HIF). HIF stabilization also decreases hepcidin, a hormone of hepatic origin, which regulates iron homeostasis. PHD inhibitors represent a novel pharmacological treatment of anemia associated with chronic diseases. Many orally active PHD inhibitors like roxadustat, molidustat, vadadustat, and desidustat are in late phase clinical trials. This review discusses the role of PHD inhibitors in the treatment of anemia associated with chronic diseases.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29712435     DOI： 10.1021/acs.jmedchem.7b01686

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  35 in total

1.  Targeted and Interactome Proteomics Revealed the Role of PHD2 in Regulating BRD4 Proline Hydroxylation.

Authors:  Luke Erber; Ang Luo; Yue Chen
Journal:  Mol Cell Proteomics       Date:  2019-06-25       Impact factor: 5.911

2.  The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation.

Authors:  Senthilnathan Palaniyandi; Reena Kumari; Sabarinath Venniyil Radhakrishnan; Ethan Strattan; Natalya Hakim; Reinhold Munker; Melissa V Kesler; Gerhard C Hildebrandt
Journal:  Transplantation       Date:  2020-12       Impact factor: 4.939

Review 3.  Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Min Li; Jiarong Lan; Feixia Dong; Peixin Duan
Journal:  Eur J Clin Pharmacol       Date:  2020-11-07       Impact factor: 2.953

4.  Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-hydroxylase and Inhibited by Some PHD Inhibitors.

Authors:  Vijesh J Bhute; James Harte; Jack W Houghton; Patrick H Maxwell
Journal:  Kidney360       Date:  2020-04-03

5.  The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion.

Authors:  Zesen Lin; Richard King; Vi Tang; Greggory Myers; Ginette Balbin-Cuesta; Ann Friedman; Beth McGee; Karl Desch; Ayse Bilge Ozel; David Siemieniak; Pavan Reddy; Brian Emmer; Rami Khoriaty
Journal:  Mol Cell Biol       Date:  2020-11-06       Impact factor: 4.272

Review 6.  Hypoxia-inducible factor-1α regulation of myeloid cells.

Authors:  C L Stothers; L Luan; B A Fensterheim; J K Bohannon
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

Review 7.  Treatment of Renal Anemia with Roxadustat: Advantages and Achievement.

Authors:  Zuo-Lin Li; Yan Tu; Bi-Cheng Liu
Journal:  Kidney Dis (Basel)       Date:  2020-01-10

8.  Aspartate/asparagine-β-hydroxylase: a high-throughput mass spectrometric assay for discovery of small molecule inhibitors.

Authors:  Lennart Brewitz; Anthony Tumber; Inga Pfeffer; Michael A McDonough; Christopher J Schofield
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

9.  Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.

Authors:  Tadao Akizawa; Manabu Iwasaki; Tetsuro Otsuka; Yusuke Yamaguchi; Michael Reusch
Journal:  Kidney Int Rep       Date:  2021-04-17

10.  Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor.

Authors:  Ruth X Wang; Morkos A Henen; J Scott Lee; Beat Vögeli; Sean P Colgan
Journal:  Gut Microbes       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.